These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37404744)

  • 1. Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study.
    Banach M; Lewek J; Pol K; Rabczenko D; Balanescu SM; Blaha V; Ceska R; Jankowski P; Surma S; Kolovou G; Liberopoulos E; Mitu F; Mitu M; Naji FH; Paragh G; Popławska M; Vrablik M; Pella D
    Front Cardiovasc Med; 2023; 10():1206551. PubMed ID: 37404744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.
    Banach M; López-Sendon JL; Averna M; Cariou B; Loy M; Manvelian G; Batsu I; Poulouin Y; Gaudet D
    Arch Med Sci; 2022; 18(2):285-292. PubMed ID: 35316922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.
    Gaudet D; López-Sendón JL; Averna M; Bigot G; Banach M; Letierce A; Loy M; Samuel R; Manvelian G; Batsu I; Henry P;
    Eur J Prev Cardiol; 2022 Feb; 28(17):1864-1872. PubMed ID: 33624041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
    Langslet G; Hovingh GK; Guyton JR; Baccara-Dinet MT; Letierce A; Manvelian G; Farnier M
    Cardiovasc Drugs Ther; 2020 Aug; 34(4):515-523. PubMed ID: 32363493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.
    Müller-Wieland D; Leiter LA; Cariou B; Letierce A; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Cardiovasc Diabetol; 2017 May; 16(1):70. PubMed ID: 28545518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
    Dufour R; Hovingh GK; Guyton JR; Langslet G; Baccara-Dinet MT; Din-Bell C; Manvelian G; Farnier M
    J Clin Lipidol; 2019; 13(1):138-147. PubMed ID: 30591415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study.
    Henry P; Cariou B; Farnier M; Lakhdari SL; Detournay B
    Arch Cardiovasc Dis; 2023 Jan; 116(1):3-8. PubMed ID: 36535853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Farnier M; Hovingh GK; Langslet G; Dufour R; Baccara-Dinet MT; Din-Bell C; Manvelian G; Guyton JR
    Atherosclerosis; 2018 Nov; 278():307-314. PubMed ID: 30293878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of alirocumab versus ezetimibe in high cardiovascular risk Chinese patients with hyperlipidemia: ODYSSEY EAST Study-Chinese sub-population analysis].
    Han YL; Ma YY; Su GH; Li Y; Li Y; Liu DF; Song R; Li JY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):593-599. PubMed ID: 32842270
    [No Abstract]   [Full Text] [Related]  

  • 10. A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.
    Cefalù AB; Garbelotto R; Mombelli G; Pirro M; Rubba P; Arca M; Borghi C; Bonomo K; Gonnelli S; Massaroni K; Tirone G; Averna M;
    Nutr Metab Cardiovasc Dis; 2022 Nov; 32(11):2638-2646. PubMed ID: 36064689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
    Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
    Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand.
    Han Y; Chen J; Chopra VK; Zhang S; Su G; Ma C; Huang Z; Ma Y; Yao Z; Yuan Z; Zhao Q; Kuanprasert S; Baccara-Dinet MT; Manvelian G; Li J; Chen R
    J Clin Lipidol; 2020; 14(1):98-108.e8. PubMed ID: 31882376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
    Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
    J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
    Kastelein JJ; Ginsberg HN; Langslet G; Hovingh GK; Ceska R; Dufour R; Blom D; Civeira F; Krempf M; Lorenzato C; Zhao J; Pordy R; Baccara-Dinet MT; Gipe DA; Geiger MJ; Farnier M
    Eur Heart J; 2015 Nov; 36(43):2996-3003. PubMed ID: 26330422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
    Bays H; Gaudet D; Weiss R; Ruiz JL; Watts GF; Gouni-Berthold I; Robinson J; Zhao J; Hanotin C; Donahue S
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3140-8. PubMed ID: 26030325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial.
    Schwartz GG; Gabriel Steg P; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Jukema JW; Kim YU; Li QH; Manvelian G; Pordy R; Sourdille T; White HD; Szarek M;
    Circulation; 2021 Mar; 143(11):1109-1122. PubMed ID: 33438437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Farnier M; Jones P; Severance R; Averna M; Steinhagen-Thiessen E; Colhoun HM; Du Y; Hanotin C; Donahue S
    Atherosclerosis; 2016 Jan; 244():138-46. PubMed ID: 26638010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
    Bays HE; Leiter LA; Colhoun HM; Thompson D; Bessac L; Pordy R; Toth PP
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.